Clinical Assessment of the External Sound Processor Worn by Patients Implanted With Codacs
Launched by COCHLEAR · Jun 3, 2014
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects implanted with a Cochlear C-DACS investigational device
- Exclusion Criteria:
- • Participation in another medical device study
- • Unwillingness or inability of the subject to comply with the study requirements
About Cochlear
Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannover, Niedersachsen, Germany
Patients applied
Trial Officials
Ernst von Wallenberg, PhD
Study Director
Cochlear
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials